Sean Kelly, DO
Internal Medicine · Washington, PANPI 1174592760
Payments from drug & device makers
Across 375 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Pfizer$956
- GSK$600
- Lilly USA, LLC$509
- AbbVie$389
- AstraZeneca$291
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,72399%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 89 | $1,144 |
| Pfizer | 63 | $956 |
| GSK | 36 | $600 |
| Lilly USA, LLC | 33 | $509 |
| AbbVie(2 entities) | 21 | $389 |
| AstraZeneca | 20 | $291 |
| Amgen | 19 | $290 |
| Johnson & Johnson | 15 | $225 |
| Boehringer Ingelheim | 14 | $217 |
| Merck | 10 | $155 |
| Amarin Pharma, Inc. | 7 | $114 |
| Bayer | 7 | $111 |
| Medtronic | 1 | $91 |
| Abbott | 3 | $66 |
| Exact Sciences | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| Sanofi-aventis U.S. LLC | 3 | $39 |
| Vivus LLC | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Radius Health, Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| CSL Behring | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Ardelyx, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
How this compares
$5,776 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 527 | $380,356 |
| JardianceEmpagliflozin | 224 | $179,469 |
| OzempicSemaglutide | 160 | $157,806 |
| XareltoRivaroxaban | 146 | $118,977 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 121 | $110,130 |
| RexultiBrexpiprazole | 25 | $37,804 |
| TrulicityDulaglutide | 28 | $26,250 |
| FarxigaDapagliflozin Propanediol | 24 | $23,573 |
| ProliaDenosumab | 14 | $23,385 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $22,839 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $20,256 |
| Repatha SureclickEvolocumab | 24 | $20,142 |
| JanuviaSitagliptin Phosphate | 35 | $19,672 |
| TradjentaLinagliptin | 23 | $18,849 |
| Repatha SyringeEvolocumab | 29 | $18,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $956 | $380,356527 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Spiriva Respimat | $217 | $217,547280 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix | $600 | $168,800258 claims |
| Novo NordiskOzempic | $1,144 | $157,806160 claims |
| Johnson & JohnsonXarelto | $225 | $118,977146 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $22 | $37,80425 claims |
| Lilly USA, LLCTrulicity | $509 | $26,25028 claims |
| MerckJanuvia, Belsomra | $155 | $24,96748 claims |
| AstraZenecaFarxiga | $291 | $23,57324 claims |
| AmgenProlia | $290 | $23,38514 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $7,80714 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $5,62312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Washington
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.